Gabelli & Co Investment Advisers’s Trillium Therapeutics Inc. TRIL Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-563,094	Closed	-$9.89M	–	537
2021 Q3	$9.89M	Buy	563,094 +548,094	+3,654%	+$6.4M	1.2%	20
2021 Q2	$146K	Hold	15,000	–	–	0.02%	353
2021 Q1	$161K	Buy	15,000 +5,000	+50%	+$61.8K	0.02%	344
2020 Q4	$147K	Buy	+10,000	New	+$144K	0.02%	264

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Gabelli & Co Investment Advisers's TRIL Position: Q4 2021 in Review

Gabelli & Co Investment Advisers sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 563,094 shares — an estimated $9.89M sold.

Gabelli & Co Investment Advisers first reported a position in TRIL in Q4 2020 and held it in 4 quarters. The position peaked at $9.89M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Gabelli & Co Investment Advisers reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 563,094 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $9.89M.
Gabelli & Co Investment Advisers first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 4 quarters.
Gabelli & Co Investment Advisers's Trillium Therapeutics Inc. position peaked at $9.89M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2021, filed 11 Feb 2022.